おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Edge Therapeutics
About
Edge Therapeutics, a biotechnology company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions.
- 1 - 10
Highlights
Details
- Last Funding Type
- Debt Financing
- Last Funding Money Raised
- $10M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2009
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.It was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 9, 2015 | Series C | $56M | 1 | — | — | Detail |
| Sep 8, 2014 | Debt Financing | $10M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Franklin Advisors
|
— | Series C |
Hercules Capital
|
— | Debt Financing |
